Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $184,057.51 in Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) insider David Malcom Rodman sold 6,349 shares of Mineralys Therapeutics stock in a transaction dated Thursday, February 12th. The stock was sold at an average price of $28.99, for a total value of $184,057.51. Following the completion of the sale, the insider owned 50,437 shares of the company’s stock, valued at approximately $1,462,168.63. The trade was a 11.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

David Malcom Rodman also recently made the following trade(s):

• On Friday, February 13th, David Malcom Rodman sold 14,055 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.44, for a total transaction of $385,669.20.
• On Monday, February 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $30.21, for a total transaction of $65,585.91.
• On Tuesday, January 20th, David Malcom Rodman sold 416 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.10, for a total transaction of $13,353.60.
• On Wednesday, January 14th, David Malcom Rodman sold 11,367 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.61, for a total transaction of $370,677.87.
• On Tuesday, January 13th, David Malcom Rodman sold 7,709 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.75, for a total transaction of $252,469.75.
• On Monday, January 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.32, for a total transaction of $205,167.36.
• On Friday, January 9th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $33.27, for a total transaction of $72,195.90.
• On Friday, January 2nd, David Malcom Rodman sold 70,037 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $35.87, for a total transaction of $2,512,227.19.
• On Monday, January 5th, David Malcom Rodman sold 192,715 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $35.02, for a total value of $6,748,879.30.

Mineralys Therapeutics Trading Down 0.9%

Shares of NASDAQ:MLYS traded down $0.26 during midday trading on Friday, hitting $27.60. The company had a trading volume of 1,068,870 shares, compared to its average volume of 1,077,399. Mineralys Therapeutics, Inc. has a 12 month low of $8.24 and a 12 month high of $47.65. The stock has a market cap of $2.18 billion, a price-to-earnings ratio of -9.36 and a beta of 0.51. The firm has a fifty day simple moving average of $33.89 and a 200 day simple moving average of $33.41.

Mineralys Therapeutics (NASDAQ:MLYS) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.14. Equities analysts forecast that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on MLYS. Wells Fargo & Company upped their price target on Mineralys Therapeutics from $50.00 to $55.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Thursday, January 22nd. Stifel Nicolaus increased their target price on shares of Mineralys Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Finally, HC Wainwright lifted their price target on shares of Mineralys Therapeutics from $52.00 to $56.00 and gave the stock a “buy” rating in a research report on Wednesday, November 12th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $47.43.

Institutional Trading of Mineralys Therapeutics

Hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC acquired a new position in shares of Mineralys Therapeutics in the first quarter valued at approximately $550,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Mineralys Therapeutics by 4.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,085 shares of the company’s stock worth $271,000 after acquiring an additional 702 shares during the period. Goldman Sachs Group Inc. lifted its position in Mineralys Therapeutics by 166.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 298,395 shares of the company’s stock valued at $4,739,000 after acquiring an additional 186,480 shares in the last quarter. Woodline Partners LP acquired a new position in Mineralys Therapeutics in the 1st quarter worth $757,000. Finally, KLP Kapitalforvaltning AS acquired a new position in Mineralys Therapeutics in the 2nd quarter worth $91,000. 84.46% of the stock is currently owned by institutional investors and hedge funds.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.